Blue Jet Healthcare Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/uw52wouug9g8qzuoieeia8au.pdf

Key Takeaways


The Margin Story: Inventory Timing, Not Deterioration

Ganesh Karuppannan: "I would actually say this is more an accounting, the way Sanjay put it across. When the inventory gets released, this overhead absorption happens. I think had we maintained a similar finished goods level like last quarter; you would not have seen this impact."

Contrast Media: The Trough and the Recovery Bet

Ganesh Karuppannan: "If we look at all the three together, there is a good probability we should actually get back to the 23 levels. I think that is our aspiration. So, that's what we are working on. So, this would actually become a new base for us."

PI & API: The Growth Engine Scaling Up

Shiven Arora: "In terms of what I can share right now, the net realization per kg improves significantly with this launch, we won't be able to disclose the volume or KL capacity. But from a criticality standpoint, and our growth journey, this is a fairly good needle mover."

Capacity Build-Out: The Multi-Year Expansion Thesis

VK Singh: "We took that, but then we felt that that was subscale because now we have spotted and in the process of finalizing a much, much larger piece of land. Therefore, it was logical for us to surrender this in view of the much larger parcel of land that we would be acquiring very shortly."

Sweeteners & Other Segments


Guidance & Commitments

CommitmentSpecificsTimeline
Gross margin sustainability53% on current portfolio mixComing quarters
Iodinated intermediate supply startCapacity ready; supply beginsQ2 FY26
Iodinated AB HCL launchBackward integration launchH2 FY26
Unit-3 Mahad commissioningContinuous processing and CMI backward integration on streamH2 FY26
Additional PI/API launchesNew launches in pharma intermediates and APIH2 FY26
Contrast media sequential growthClient offtake ramp-up drives H2 growthH2 FY26
Multipurpose GMP plant at Mahad~30-reactor plant for pharma intermediates and peptide fragmentsH2 FY27
Balance Unit-3 capex₹200 cr to be incurredUp to FY27
Iodinated molecule full-year impactFull-year contribution visibleFY27
NCE molecule growthGrowth expectedFY27-28
New contrast media opportunitiesAdditional capacities for contrast mediaFY28-29
Capacity addition1,000 KL to be added, backed by client lock-insNext 2-3 years
Asset turn targetCompany-level asset turns of 2.5–3xNext 5 years
New land parcel announcementMuch larger parcel being finalizedShortly
Larger capex outlay announcementBigger outlay for future expansion to be communicatedShortly

Key Metrics

MetricQ1 FY26
Revenue from operations₹354.8 cr, up 4% sequentially and 118% YoY
EBITDA₹120 cr, margin 34.1%, down 7% sequentially, up 173% YoY
PAT₹91.2 cr, net margin 25.7%, down from Q4, up 148% YoY
Gross margin48.5%, down 6.5 ppt from 55% in Q4; 4.4 ppt of decline from inventory drawdown, 2.1 ppt from product mix
PI and API segment revenue growth8.2% QoQ
Artificial sweetener segment revenue growth17.4% QoQ
Contrast media segment revenue₹97 cr, down 3.9% QoQ
Cash and treasury instruments₹270 cr
CAPEX incurred in Q1₹28 cr
Capacity utilization (company level)~75%
Capacity utilization (Unit-2 Ambernath, PI segment block)60%
Active RFPs~20, up from 11 or 12 last year; 6 in late phase III or commercial
Contrast media end formulation market size$6.7 bn, projected to reach $10 bn in the next few years
GST demand (one-time impact on EBITDA)₹2.7 cr, impacted EBITDA by ~0.7%